title: Primary add-on of ziprasidone in sertraline treatment of posttraumatic stress disorder: lessons from a stopped trial?
authors.forename: Michael
authors.initials: M
authors.lastname: Kellner
authors.forename: Christoph
authors.initials: C
authors.lastname: Muhtz
authors.forename: Klaus
authors.initials: K
authors.lastname: Wiedemann
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000941:ethics; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D020280:Sertraline / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy*; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D010879:Piperazines; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D013844:Thiazoles; C092292:ziprasidone